BDTX - Black Diamond Therapeutics Inc logo

Black Diamond Therapeutics Inc

BDTX

Black Diamond Therapeutics develops precision oncology therapies targeting genetically defined tumors. Its lead candidates include silevertinib for non-small cell lung cancer and glioblastoma, and BDTX-4933 for KRAS, NRAS, and BRAF mutations.

โš•๏ธ Healthcare NASDAQ Listed 2020 $ USD
$1,000 invested 5 years ago โ†’$232today

Score Overview

1 Year
Score
Net Growth-290.26%
Net TrendShrank
Net Income Consistencyโ€”
Rev Growth-100.00%
Rev TrendShrank
Revenue Consistencyโ€”
5 Years
Scoreโ€”
Net Growth66.12%
Net Trend80%
Net Income Consistencyโ€”
Rev Growthโ€”
Rev Trend20%
Revenue Consistencyโ€”
All Time
Scoreโ€”
Net Growth36.72%
Net Trend67%
Net Income Consistency
Rev Growthโ€”
Rev Trend17%
Revenue Consistency

Explore the 2021 public Archive ranking โ†’

Where Black Diamond Therapeutics Inc has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. BDTX does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-23
$ 1.88โ€”
1 Year2025-10-23
$ 3.88-51.55%
5 Years2021-10-22
$ 8.10-76.79%
All Time2020-01-30
$ 39.48-95.24%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 0.00-$ 42M$ 110M
2025$ 70M$ 22M$ 128M
2024$ 0.00-$ 69M$ 98M
2023$ 0.00-$ 82M$ 131M
2022$ 0.00-$ 91M$ 122M
2021$ 0.00-$ 125M$ 209M
IPO2020$ 0.00-$ 67M$ 315M
BDTX - Black Diamond Therapeutics Inc logo

Black Diamond Therapeutics Inc fundamental performance

Across Black Diamond Therapeutics Inc's full reported history, from 2020 to 2025, revenue grew from $ 0.00 to $ 70M and net income went from -$ 67M to $ 22M. Revenue increased in 17% of the years measured; net income in 67%.

Membership

Explore BDTX with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,112 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year ยท Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies